Clinical Trial Update: Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial of lenalidomide as a single agent in adults with relapsed/refractory acute lymphoblastic leukemia was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Revlimid (lenalidomide) (lenalidomide)

Snippet

Sponsor: Stanford University | Conditions: Leukemia, Relapsed Adult Acute Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2014-11-10